SLSN

Solésence has a genuine top-line story: revenue grew 18.6% to $62.1M in FY2025 (a doubling since 2021's $29.5M), driven by the pivot into consumer Solésence prestige skincare — a new customer went from 0% to 16% of sales and Consumer Products #1 held ~29%. But that growth is not translating into value. Gross profit was flat (-0.8%) despite the revenue surge, so gross margin compressed to 25.9%; operating income fell 69.4% to $1.57M and diluted EPS dropped 71.4% to $0.02. Net income of $1.79M was down 57.7% year-over-year, and the multi-year track record is erratic (losses in FY2022–2023, a $4.24M peak in FY2024, then this slide). Management's own MD&A concedes margins are hostage to demand cyclicality, commodity metals costs, and their ability to absorb fixed manufacturing overhead — this is a low-margin contract-scale business, not a high-return brand yet.

The balance sheet is where the call turns from lukewarm to negative. Operating cash flow swung to -$8.57M (a 534.7% deterioration) against just $1.29M of cash on hand — the company earned an accounting profit while bleeding real cash, a classic working-capital/inventory red flag. That is corroborated by the rising inventory reserve ($2.72M in 2025 vs $1.99M in 2024) on aging, obsolete, and expiring materials, and a $98.6M accumulated deficit. Liquidity isn't immediately fatal — current assets of $28.8M cover current liabilities of $13.9M (~2.1x) and reported debt is negligible — but funding an $8.6M burn off a $1.3M cash balance points toward equity dilution or distress financing, a real risk for a 70.6M-share micro-cap trading at $0.68.